GRM5 and fragile X syndrome: Specifically, the FX-LEARN project evaluating the effects of the selective metabotropic glutamate receptor type 5 (mGluR5) antagonist on language learning in young children with FXS (NCT02920892) is an example of a targeted treatment over a long time period that would significantly benefit from a comprehensive foundation of developmental understanding in FXS.